Masitinib 2nd Line versus Sunitinib in Advanced GIST

Masitinib 2nd Line versus Sunitinib in Advanced GIST

Gastrointestinal Stromal Tumor

Unknown

3

Start Date 05/15/2012

Age of Trial (yrs) 12.5

Gleevec-resistant

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

AB110002

AB Science

Axel Le Cesne, M.D., Ph.D. +33 1 42 11 43 16 lecesne@igr.fr

Randomized

Oral

AB Science Press Release 5/15/2011: This is a phase 3, multicenter, randomized, open-label, controlled, two-parallel group study evaluating the efficacy and safety of masitinib as compared with sunitinib (Sutent®) in GIST patients after progression under imatinib (Gleevec®). This study will recruit around 200 patients from 50 sites around the world, randomized with a 1:1 ratio between masitinib and sunitinib. The primary end-point is overall survival (OS).